Overlapping type 2, barrier, and remodeling endotypes shape clinical expression in eosinophilic esophagitis.

Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease of the esophagus in which symptoms, histologic activity, endoscopic severity, epithelial dysfunction, and fibrostenotic remodeling frequently diverge. Peak eosinophil density remains central to diagnosis and response assessment, but it represents only one component of a broader epithelial-immune and structural process. This review integrates epithelial alarmins, local type 2 immunity, IL-13-driven epithelial programming, eosinophil-mast-cell effector activity, and stromal remodeling within an endotype-to-phenotype framework. We propose that inflammatory, barrier-dominant, relapsing, treatment-responsive, fibrostenotic, and mixed clinical patterns reflect overlapping programs rather than discrete diseases. The strength of evidence differs across the framework: IL-13-associated epithelial activity, eosinophil-mast-cell injury, and remodeling pathways are supported by human tissue, treatment, and functional studies, whereas alarmin-dominant, barrier-relapse, and biomarker-matched treatment constructs remain largely mechanistic or hypothesis-generating. Eosinophils remain biologically active effector cells, but their number alone does not capture degranulation, mast-cell activity, epithelial repair, or accumulated structural injury. We therefore distinguish symptomatic, histologic, endoscopic, molecular, and structural or functional remission and emphasize the complementary roles of EREFS, broader histologic scoring, and structural assessment. The proposed model is a conceptual synthesis of published evidence, not a validated routine treatment-selection algorithm, but it may support future longitudinal validation and stratified research.